HK1123311A1 - Diagnosis and treatment of cancers and other conditions - Google Patents

Diagnosis and treatment of cancers and other conditions

Info

Publication number
HK1123311A1
HK1123311A1 HK09101899.1A HK09101899A HK1123311A1 HK 1123311 A1 HK1123311 A1 HK 1123311A1 HK 09101899 A HK09101899 A HK 09101899A HK 1123311 A1 HK1123311 A1 HK 1123311A1
Authority
HK
Hong Kong
Prior art keywords
cancers
diagnosis
treatment
conditions
proline
Prior art date
Application number
HK09101899.1A
Other languages
English (en)
Inventor
Angus Gidley-Baird
Julian Alexander Barden
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2579A external-priority patent/AUPR257901A0/en
Priority claimed from AUPR5890A external-priority patent/AUPR589001A0/en
Priority claimed from AUPR5891A external-priority patent/AUPR589101A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Publication of HK1123311A1 publication Critical patent/HK1123311A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023Lung
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038Kidney, bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
HK09101899.1A 2001-01-17 2009-02-27 Diagnosis and treatment of cancers and other conditions HK1123311A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPR2579A AUPR257901A0 (en) 2001-01-17 2001-01-17 Diagnosis and treatment of malignant lymphoma
AUPR5890A AUPR589001A0 (en) 2001-06-22 2001-06-22 An antibody cancer therapeutic
AUPR5891A AUPR589101A0 (en) 2001-06-22 2001-06-22 Diagnosis of cell cancers using an antibody to non-functionalP2X, receptors
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
HK1123311A1 true HK1123311A1 (en) 2009-06-12

Family

ID=27507500

Family Applications (3)

Application Number Title Priority Date Filing Date
HK05103553.8A HK1070903A1 (en) 2001-01-17 2005-04-26 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
HK09101899.1A HK1123311A1 (en) 2001-01-17 2009-02-27 Diagnosis and treatment of cancers and other conditions
HK10103195.5A HK1138013A1 (en) 2001-01-17 2010-03-29 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK05103553.8A HK1070903A1 (en) 2001-01-17 2005-04-26 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK10103195.5A HK1138013A1 (en) 2001-01-17 2010-03-29 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Country Status (15)

Country Link
US (10) US7326415B2 (xx)
EP (2) EP1360203B1 (xx)
JP (2) JP4384852B2 (xx)
CN (2) CN100497385C (xx)
AT (2) ATE418565T1 (xx)
AU (1) AU2003235005B2 (xx)
CA (1) CA2434490C (xx)
DE (1) DE60230482D1 (xx)
DK (2) DK1360203T3 (xx)
ES (2) ES2320421T3 (xx)
HK (3) HK1070903A1 (xx)
MY (1) MY158262A (xx)
PT (1) PT1360203E (xx)
TW (1) TWI319011B (xx)
WO (1) WO2002057306A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
JP4467973B2 (ja) * 2001-09-03 2010-05-26 イントリート ピーティーワイ リミテッド 非機能性p2x7リセプターに対応する抗体、癌及びその他の症状の診断及び治療
JP4413617B2 (ja) * 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Chlamydiatrachomatisに対する免疫化
GB0229139D0 (en) * 2002-12-13 2003-01-15 Glaxo Group Ltd Gene polymorphisms
WO2007146061A2 (en) * 2006-06-09 2007-12-21 University Hospitals Of Cleveland Cell collection and disease screening
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
EP2201026B1 (en) * 2007-09-14 2017-01-04 Biosceptre (Aust) Pty Ltd Novel p2x7 epitopes
ATE542139T1 (de) * 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
CN102143978B (zh) * 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
AU2009329501B2 (en) * 2008-12-19 2015-11-26 Ablynx N.V. Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4
JP5936067B2 (ja) 2009-08-20 2016-06-15 バイオセプター・(オーストラリア)・ピーティーワイ・リミテッド 抗p2x7受容体抗体およびその断片
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
EP2516470B1 (en) 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
ES2656971T3 (es) 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7
WO2012149334A2 (en) * 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP2726095B1 (en) 2011-07-01 2018-06-06 Biosceptre (Aust) Pty Ltd Combination therapy
AU2017346936B2 (en) 2016-10-21 2022-10-06 Biosceptre (Aust) Pty Ltd Cytotoxic particles
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
KR20210049090A (ko) 2018-07-05 2021-05-04 인사이트 코포레이션 A2a/a2b 억제제로서 융합된 피라진 유도체
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
US12060433B2 (en) 2020-01-03 2024-08-13 Incyte Corporation CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
BR112022013236A2 (pt) 2020-01-03 2022-09-06 Incyte Corp Anticorpos anti-cd73 e usos dos mesmos
US20220233529A1 (en) 2020-12-29 2022-07-28 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2024055076A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd Methods of detecting immune cells
WO2024055077A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd Enrichment of engineered immune cells
WO2024055075A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1141314A (en) * 1914-12-19 1915-06-01 Eugene W Caldwell Photographic developing apparatus.
US2191508A (en) * 1939-02-06 1940-02-27 Stuart Robert Photographic film carrier and development receptacle
US3010460A (en) * 1958-07-03 1961-11-28 Geo B Hart Inc Apparatus for wetting absorbent bodies for moistening and supporting plant parts
US3077155A (en) * 1960-08-08 1963-02-12 Pako Corp Device for treating photographic sheet material
US3121438A (en) * 1961-01-16 1964-02-18 Union Carbide Corp Open head container and cover therefor
US3952756A (en) * 1974-06-14 1976-04-27 Purex Corporation Semi automatic parts cleaning machine
US4302273A (en) * 1980-06-04 1981-11-24 Rca Corporation Etching tank in which the solution circulates by convection
US4305413A (en) * 1980-07-25 1981-12-15 Ecology, Inc. Cleaning apparatus
US4550579A (en) * 1984-04-13 1985-11-05 Frank Clifford G Apparatus for the dyeing of shaped articles
US5104727A (en) * 1989-06-16 1992-04-14 W. L. Gore & Associates, Inc. Air bag laminates
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
JPH0756015A (ja) * 1993-08-18 1995-03-03 Sony Corp カラーフィルタの製造方法
US5985603A (en) 1994-05-27 1999-11-16 Glaxo Group Limited P2x receptor DNA and protein sequence
US5660640A (en) * 1995-06-16 1997-08-26 Joray Corporation Method of removing sputter deposition from components of vacuum deposition equipment
US5981218A (en) 1995-08-09 1999-11-09 Bristol-Myers Squibb Company Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides
EP0907729A1 (en) 1996-04-30 1999-04-14 Smithkline Beecham Plc HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US5851307A (en) * 1997-04-28 1998-12-22 Advanced Micro Devices, Inc. Method for in-situ cleaning of polysilicon-coated quartz furnaces
US5849091A (en) * 1997-06-02 1998-12-15 Micron Technology, Inc. Megasonic cleaning methods and apparatus
US5906216A (en) * 1997-10-10 1999-05-25 Barlet; Bruce N. Denture cleaning device
EP1086223B1 (en) * 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6055694A (en) * 1998-11-30 2000-05-02 Tsk America, Inc. Wafer scrubbing machine
WO2000050458A1 (en) 1999-02-26 2000-08-31 Smithkline Beecham Corporation Cloning of a p2y-like 7tm receptor (axor17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
DK1360203T3 (da) * 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
JP4467973B2 (ja) 2001-09-03 2010-05-26 イントリート ピーティーワイ リミテッド 非機能性p2x7リセプターに対応する抗体、癌及びその他の症状の診断及び治療
PL1473367T3 (pl) 2003-04-17 2007-11-30 Affectis Pharmaceuticals Ag Środki i sposoby diagnozowania zaburzeń afektywnych
WO2006136004A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
WO2008043145A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
EP2201026B1 (en) 2007-09-14 2017-01-04 Biosceptre (Aust) Pty Ltd Novel p2x7 epitopes
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
JP5936067B2 (ja) 2009-08-20 2016-06-15 バイオセプター・(オーストラリア)・ピーティーワイ・リミテッド 抗p2x7受容体抗体およびその断片
EP2516470B1 (en) 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
ES2656971T3 (es) 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7
EP2726095B1 (en) 2011-07-01 2018-06-06 Biosceptre (Aust) Pty Ltd Combination therapy

Also Published As

Publication number Publication date
MY158262A (en) 2016-09-30
ES2383712T3 (es) 2012-06-25
HK1070903A1 (en) 2005-06-30
US7326415B2 (en) 2008-02-05
US7888473B2 (en) 2011-02-15
US10450380B2 (en) 2019-10-22
ATE548383T1 (de) 2012-03-15
EP1360203A4 (en) 2005-06-22
EP1360203B1 (en) 2008-12-24
US8399617B2 (en) 2013-03-19
US7531171B2 (en) 2009-05-12
US20130245226A1 (en) 2013-09-19
AU2003235005A8 (en) 2003-09-11
US20090192293A1 (en) 2009-07-30
US9663584B2 (en) 2017-05-30
EP1961767B1 (en) 2012-03-07
US20110092674A1 (en) 2011-04-21
US20140323693A1 (en) 2014-10-30
EP1360203A1 (en) 2003-11-12
EP1961767A2 (en) 2008-08-27
WO2002057306A1 (en) 2002-07-25
CN1541222A (zh) 2004-10-27
JP4457169B2 (ja) 2010-04-28
US20200071419A1 (en) 2020-03-05
JP2004528286A (ja) 2004-09-16
JP4384852B2 (ja) 2009-12-16
ATE418565T1 (de) 2009-01-15
CN101555283A (zh) 2009-10-14
CN100497385C (zh) 2009-06-10
PT1360203E (pt) 2009-04-03
AU2003235005B2 (en) 2007-09-20
US20120059151A1 (en) 2012-03-08
CN101555283B (zh) 2012-03-21
DE60230482D1 (de) 2009-02-05
CA2434490A1 (en) 2002-07-25
AU2003235005A1 (en) 2003-09-11
US8080635B2 (en) 2011-12-20
DK1360203T3 (da) 2009-04-20
US20150274839A1 (en) 2015-10-01
US20170327592A1 (en) 2017-11-16
EP1961767A3 (en) 2008-10-29
DK1961767T3 (da) 2012-05-29
HK1138013A1 (en) 2010-08-13
JP2009235074A (ja) 2009-10-15
US8709425B2 (en) 2014-04-29
CA2434490C (en) 2014-06-03
TWI319011B (en) 2010-01-01
ES2320421T3 (es) 2009-05-22
US20040142342A1 (en) 2004-07-22
US20080131438A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
HK1123311A1 (en) Diagnosis and treatment of cancers and other conditions
MXPA02004666A (es) Gelatinas recombinantes.
GB0227346D0 (en) 741
HK1028417A1 (en) Cysteine rich receptors-train
AU2001247788A1 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
IL174037A0 (en) Fsh mutant, its preparation and use
HK1072948A1 (en) Ifnar2 mutants, their production and use
EP1218392A4 (en) GENE THE PROTEINS ENCODE WHICH PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER USE HAVE
EP1194534A4 (en) NOVEL GENES ENCODING PROTEINS THAT CAN BE USED IN DIAGNOSTIC, PREVENTIVE, THERAPEUTIC OR OTHER AREAS
WO2001011039A3 (de) Sequenzvarianten des menschlichen 1-adrenozeptorgens und ihre verwendung
DE60042056D1 (de) Menschliche Carnosinase 2
AU9362801A (en) A novel polypeptide, a human protein 10 containing a group and the polynucleotide encoding the polypeptide
EP1240198A4 (en) GENES ENCODING PROTEINS WITH PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER APPLICATIONS
AU2002357666A1 (en) 69583 and 85924, novel human protein kinase family members and uses therefor
AU4823901A (en) A novel polypeptide, glucose transport-associated human protein 10 and the polynucleotide encoding the polypeptide
AU7376901A (en) A novel polypeptide, human protein 17 stag3 (stromal antigene) and the polynucleotide encoding the polypeptide
AU2002235434A1 (en) 15569, a novel human g protein coupled receptor and uses therefor
AU2002257361A1 (en) Peptide beta-strand mimics based on 1,2-dihydro-3(6h)-pyridinone
AU2002326343A1 (en) 87144, human amino acid transporter family member and uses therefor
AU5815601A (en) A novel polypeptide, human peroxydase protein 9 and the polynucleotide encoding the polypeptide
AU7623501A (en) A novel polypeptide, a cockerel wing-deforming human protein fh2-13 and the polynucleotide encoding the polypeptide
AU7624201A (en) A novel polypeptide, a human atp dependent-uncoiling enzyme protein 10 and the polynucleotide encoding the polypeptide
AU7623901A (en) A novel polypeptide, a human protein 9 similar to inclusin, and the polynucleotide encoding the polypeptide
AU5815101A (en) A novel polypeptide, mitotic cycle regulation human protein 9 and the polynucleotide encoding the polypeptide
AU4225101A (en) A novel polypeptide, a human transglutaminase 12 and the polynucleotide encodingthe polypeptide

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220113